Pharma Bum (@CaptainTight) header
Pharma Bum (@CaptainTight) profile picture

20+ years in rare disease clinical trials, 2 FDA approvals. Biotech stocks in plain english, no PhD required. Data first, opinions second. Professional Lurker.

California, USA
Joined March 2009
started out the year in 1st place 🥇
#Biopick2026 wk1. Here we go again, starting new contest with a few bangers already👇 1. $zntl +173% 🚀 2. $alms +118% 3. $eras +88% Individual leaders: 1. @CaptainTight (zntl) 2. @DavidBautz (zntl) 3. @biotechbeta (zntl) Full Standings: drive.google.com/file/d/1W-Q…
1
4
1,614
the $NVO bull case treats $LLY like a peer. novo is one franchise losing share in its own market. lilly is retatrutide behind tirzepatide behind a manufacturing buildout nobody else can fund. meanwhile $VKTX: one oral data readout from being the third chair at a two-chair table. levels to this.
1
1
134
Biotech is the strongest AI use case in any industry, because its economics run on time. Every efficiency gain drops straight to profit, and every month cut from development is a month of patent-protected sales gained on the other end. $xbi
Stanley Druckenmiller just said: We’re looking for AI use cases as opposed to infrastructure Infrastructure might be a good tactical trade, but I don’t think that’s going to be the big scoop they were for us before. We think AI use cases could be that If there’s going to be another big push in the market that’s where I think we’ll want to go
19
$OMER -19% midday after q3: yartemlea sales jumped 30% to $41.8M, but a $62M non-cash charge swung it to a $57.4M loss. the drug is selling. the accounting is ugly. tell me why i'm wrong.
22
love twitter right now ❤️
1
37
there’s some really terrible people getting wrecked right now. i’ll take this pain with a smile on my face (and 50% cash ready to deploy). 😃
1
28
it’s gonna be painful but this is what we need (and deserve) 🇺🇸
24
Biden’s market fucking sucks!
1
1
51
the slow sell off has already begun, again today… 🩸
23
what saved me in this market is a propensity to take profits too early (ie. not let runners run), and take loses when a trade isn’t working.
1
1
43
still down ~12% from ATHs on 30Sep
15
Pharma Bum retweeted
Citadel dumped 94% of its $SPCX position and opened a $221M position in $RKLB 🔥 @grok is Ken Griffin cooking here?
58
44
7
721
110,133
$SLS +7% premarket, halted on a phase 3 win in leukemia: patients lived 24.0 months vs 14.7 on best available care, 41% lower risk of death. survival wins like that are rare in AML. tell me why i'm wrong.
156
winners: $CGON +14.0% $TU +12.2% $MOH +11.3% $HTHT +8.9% losers: $AADX -18.7% $SMMT -16.5% $GDS -14.7% $USAR -12.6%
51
cash burn: $SANA holds $121.7m, burns $34.5m a quarter. 3 quarters of runway. dilution by spring.
60
Pharma Bum retweeted
$KURA CEO acquires $1.5 million dollars at open market! $XBI $IBB
3
13
4
50
8,834
good thing we have the best and brightest at the wheel
This is a big one. We found malicious JavaScript being served through Optimizely to some of the world's largest websites. 178 organisations affected, with everything from crypto theft and card skimming to iOS exploits. Zoom, BBC, CNN, HSBC, Salesforce, GitLab, KLM, IKEA, Equifax, Ledger. The list goes on... Full list in the post. blog.report-uri.com/worlds-l…
41
BIOPHARMA BREAKOUTS: $CGON +14.0% on 8.6x volume; $URGN +7.3% on 4.4x volume. two names, both loud.
73
flipped: $DRTS +6.1% open, -10.5% close held: $SMMT -10.2% open, -16.5% close $CGON +23.7% open, +14.0% close
1
84
4 decisions in the next 30 days: $SVRA - FDA decision Nov 22 (molgramostim for rare lung disease); $BBIO - FDA decision Nov 27 (BBP-418 for muscle disease); $VRTX - FDA decision Nov 30 (povetacicept for kidney disease); $COGT - FDA decision Nov 30 (bezuclastinib for gut tumors);
140